Eagle IP is excited to announce that Jennifer Che, President and Managing Director, will be attending the BIO 2025 International Conference, taking place from June 16-19 at the Boston Convention and Exhibition Centre. Jennifer will be participating in some events together with Hong Kong’s Science and Technology Park (HKSTP), who is hosting the Hong Kong Pavilion at BIO, sending a large delegation of attendees, as well as organizing several events.

This premier biotechnology event attracts over 17,000 professionals from around the globe, featuring networking opportunities, educational sessions, and an exhibition hall showcasing the latest innovations in the industry. Jennifer is looking forward to engaging with fellow attendees and exploring potential collaborations. She invites anyone attending the conference to reach out for a meeting to discuss opportunities, exchange ideas, or simply connect.

About BIO 2025
The BIO International Convention is the world’s largest biotechnology event, providing a platform for networking, learning, and collaboration. Attendees can participate in sessions covering the latest trends, regulatory updates, and scientific advancements, making it an invaluable experience for professionals in the biotech sector.

About Eagle IP
EAGLE IP is a specialized patent firm based in Greater China that facilitates the transfer of new technology from the research environment into the marketplace. Our team of Chinese and US patent practitioners possesses strong cross-border IP knowledge, industry experience, and deep technical expertise. We specialize in China patent strategy, patent drafting and prosecution, patent invalidations, cross-border IP issues, global patent portfolio strategy & management, and Hong Kong patent matters. Our management system is ISO 9001 certified for excellent quality control and management. Should you have any questions, please feel free to contact us at [email protected]

If you won’t be able to attend BIO 2025 but will be in Boston and would like to schedule a meeting, please let us know.

We are looking forward to seeing you in Boston!

我們過去活動

Recommended Insights

What Kind of Damage Awards Can You Get in China?

2022年6月16日
Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

2021年4月30日
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
Top crossarrow-right